Atrial fibrillation (AF) is the most common cardiac arrhythmia, with its prevalence increasing significantly in older adults and individuals with comorbidities [1]. Beyond being a major contributor to stroke risk, AF is associated with a range of adverse outcomes, including increased mortality, heart failure, cognitive decline, and a diminished quality of life (QoL) [2,3]. Additionally, AF may be the epiphenomenon of an undiagnosed underlying cardiovascular disease (CVD). Notably, approximately 30 % of patients with AF are asymptomatic, yet their prognosis in terms of stroke risk and mortality is comparable to that of symptomatic patients [4].
